Floatz logo

Lixisenatide

Type II Diabetes Mellitus

Sanofiprotein_peptidePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

142 Active assets in the Type II Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB

View all 50 →

Same molecule, other indications

Lixisenatide is also rated in:

type 2 diabetes mellitusDormant
BB
Indicative ·
66 / 100
View asset →
Parkinson diseaseDormant
CCC
Indicative ·
51 / 100
View asset →
diabetes mellitusDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →